HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and validity of mechanical thrombectomy and thrombolysis on severe cerebral venous sinus thrombosis.

AbstractBACKGROUND:
Although the majority of patients with cerebral venous sinus thrombosis (CVST) obtain an optimistic clinical outcome after heparin or warfarin treatment, there remains a subgroup of patients who do not respond to conventional anticoagulation treatment. These patients, especially younger people, as documented by hospital-based studies, have a high morbidity and mortality rate.
OBJECTIVE:
To verify the safety and efficacy of a dual mechanical thrombectomy with thrombolysis treatment modality option in patients with severe CVST.
METHODS:
Fifty-two patients diagnosed with CVST were enrolled and treated with mechanical thrombectomy combined with thrombolysis. Patients underwent urokinase 100 to 1500 × 10 IU intravenous sinus injection via a jugular catheter after confirming diagnoses of CVST by using either magnetic resonance imaging/magnetic resonance venography or digital subtract angiography. Information obtained on the patients included recanalization status of venous sinuses as evaluated by magnetic resonance venography or digital subtract angiography at admission, during operation, and at 3- and 6-month follow-up after treatment.
RESULTS:
The percentage of patients that showed complete and partial recanalization were 87% and 6%, respectively, after mechanical thrombectomy combined with thrombolysis treatment; 8% of the patients showed no recanalization. The modified Rankin Scale scores were 1.0 ± 0.9, 0.85 ± 0.63, and 0.37 ± 0.53 for discharge, and 3- and 6-month follow-up, respectively. A total of 6 patients died despite receiving aggressive treatment. No cases of relapse occurred after 3 to 6 months of follow-up.
CONCLUSION:
Thrombectomy combined with thrombolysis is a safe and valid treatment modality to use in severe CVST cases or in intractable patients that have shown no adequate response to antithrombotic drugs.
AuthorsGuangwen Li, Xianwei Zeng, Mohammed Hussain, Ran Meng, Yi Liu, Kevin Yuan, Chaitanya Sikharam, Yuchuan Ding, Feng Ling, Xunming Ji
JournalNeurosurgery (Neurosurgery) Vol. 72 Issue 5 Pg. 730-8; discussion 730 (May 2013) ISSN: 1524-4040 [Electronic] United States
PMID23313983 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Chemical References
  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Combined Modality Therapy
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Radiography
  • Sinus Thrombosis, Intracranial (diagnostic imaging, therapy)
  • Thrombectomy (adverse effects, methods)
  • Thrombolytic Therapy (adverse effects, methods)
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: